Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Goal concept. Human hand in dotted pop art style pointing on the target for red paper plane. Vector illustration

Duchenne muscular dystrophy

Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA

Analysts at BMO Capital Markets expect the lack of other exon-44-skiping therapies to facilitate a “smooth” approval process for Avidity’s del-zota.

September 11, 2025

2 min read

Tristan Manalac

Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company

Layoffs

Merck Abandons $1.3B R&D Center in London, Boots 125 Employees

Claiming that the domestic market undervalues pharma innovation, Merck has decided to pull the plug on all of its R&D efforts in the U.K.

September 11, 2025

1 min read

Tristan Manalac

THOUGHT LEADERSHIP

Webinar: Driving Biopharma Engagement: How Thought Leadership and Marketing Fuel Lead Generation

Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. This webinar will show leaders how strategic insights and targeted outreach can turn awareness into high-converting leads. Watch now.

September 10, 2025

1 min read

BioSpace Insights

Funding

Odyssey Rebounds Off Failed IPO With $213M Series D

The autoimmune and inflammatory disease–focused company canceled plans to go public earlier this year as the IPO window slammed shut.

September 10, 2025

1 min read

Dan Samorodnitsky

Business people standing and climbing up to the growth bars, helping each other, working as team and looking for the better deals in future

Layoffs

Novo’s Headcount Rose 81% in Five Years as Revenue Climbed

As Novo Nordisk cuts 9,000 people from its organization in a restructuring effort, BioSpace looks back on the Danish pharma company’s rise.

September 10, 2025

1 min read

Annalee Armstrong

Layoffs

Lundbeck Offloads Assets to Three Partners as it Exits 27 Markets, Leaving 602 Jobless

These 27 markets, comprising countries across Asia, Europe and South America, together contributed some 12% of Lundbeck’s earnings in 2024.

September 10, 2025

1 min read

Tristan Manalac

Set your goals is shown using the collage with aim and the hand. Business targeting, aiming, focus concept and way to achieve a goal

Immunology and inflammation

Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful

Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

September 10, 2025

2 min read

Tristan Manalac

Creative collage image young man builder architect engineer occupation lungs healthcare illness disease drawing background.

Lung cancer

Cullinan, Taiho’s NSCLC Hopeful Shows ‘Strong Activity,’ Clearing Road to FDA

Cullinan Therapeutics and Taiho Oncology’s zipalertinib elicited promising response rates in two mid-stage studies of non-small cell lung cancer patients with typical and uncommon EGFR mutations.

September 10, 2025

2 min read

Tristan Manalac